Fig. 1: sVNT multiplex assay shows relative ACE2 binding affinity to determine the sarbecovirus antibody profile which correlates with plate and viral based assays.
From: Priming conditions shape breadth of neutralizing antibody responses to sarbecoviruses
a The % antibody inhibition of ACE2 binding to RBD was determined for convalescent samples following SARS-CoV-2 infection from day 30–60 (n = 20 subjects), day 80–270 (n = 20 subjects), day 365 (n = 22 subjects), and represented as a heatmap (b). ^Omicron sVNT bead-based results, data following uses plate-based results. a Dotted line indicates 20% inhibition as a positive result based on limit of quantification, and data represented mean+/− stdev and individual samples shown, grey shading indicates SARS-CoV-1 clade. a, b Kruskal-Wallis multiple comparisons test, *p < 0.05. Spearman correlation analysis (r) analysis for (c) Ancestral wild type SARS-CoV-2 RBD plate-based sVNT versus SARS-CoV-2 infectious virus PRNT50, (d) bead based sVNT versus SARS-CoV-2 infectious virus PRNT50, and e wild type SARS-CoV-2 RBD plate-based sVNT versus bead based sVNT. f Bland Altman analysis of wild type SARS-CoV-2 RBD plate-based sVNT versus bead based sVNT results. f The red and green areas show the limits of agreement (Upper limit of agreement: 49.67, Lower limit of agreement: −24.61). c–e Spearman correlation analysis (r), data represents the individual data, dotted lines show 95% confidence bands of the best-fit line. Pre-pandemic plasma samples (n = 30) were used as negative controls for antibody for inhibition of ACE2 binding of the 16-plex RBD panel for % inhibition as = 100*(Mean FI of 30 negative pre pandemic samples - individual FI)/Mean FI of 30 negative pre pandemic samples. Samples were run in duplicate for the sVNT assay and experiments were repeated twice.
